Literature DB >> 7855617

Genetics of renal-cell carcinoma and evidence for a critical role for von Hippel-Lindau in renal tumorigenesis.

J R Gnarra1, M I Lerman, B Zbar, W M Linehan.   

Abstract

Using a genetic linkage-based positional cloning approach the VHL gene was identified at chromosome 3p25.5. VHL is mutated in the germlines of affected individuals, and in VHL-associated tumors the mutation is almost always exposed by virtue of chromosomal deletion of the inherited wild-type allele. VHL is also frequently mutated in sporadic, nonpapillary RCC and in familial RCC. This was predicted because such tumors are histologically similar to VHL-associated renal tumors. Knowledge that VHL plays a critical role in sporadic RCC should aid in the future diagnosis and treatment of this malignancy. Detailed analyses of the biology of individual mutations will be required to determine whether the inherited VHL mutations or acquired sporadic mutations cause loss of protein function or have dominant-negative affects. However, the nature of the VHL protein is at present unclear and a complete understanding its function will only be expected after the cloning of the full-length gene.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7855617

Source DB:  PubMed          Journal:  Semin Oncol        ISSN: 0093-7754            Impact factor:   4.929


  18 in total

1.  Molecular pathology of renal cell carcinoma.

Authors:  S Störkel
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  Two synchronous malignancies: nodular melanoma and renal cell carcinoma in a patient with an underlying germline BRCA2 mutation.

Authors:  Anson Snow; Charite Ricker; Gino K In
Journal:  BMJ Case Rep       Date:  2019-06-20

3.  An alternative route for multistep tumorigenesis in a novel case of hereditary renal cell cancer and a t(2;3)(q35;q21) chromosome translocation.

Authors:  D Bodmer; M J Eleveld; M J Ligtenberg; M A Weterman; B A Janssen; D F Smeets; P E de Wit; A van den Berg; E van den Berg; M I Koolen; A Geurts van Kessel
Journal:  Am J Hum Genet       Date:  1998-06       Impact factor: 11.025

Review 4.  VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.

Authors:  Brian I Rini
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

5.  Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

Authors:  Michael S Gordon; Michael Hussey; Raymond B Nagle; Primo N Lara; Philip C Mack; Janice Dutcher; Wolfram Samlowski; Joseph I Clark; David I Quinn; Chong-Xian Pan; David Crawford
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

6.  [Von-Hippel-Lindau gene mutation types. Association of gene expression signatures in clear cell renal cell carcinoma].

Authors:  V D Luu; B Fischer; A von Teichman; G Boysen; K Mertz; P Zimmermann; H Moch; P Schraml
Journal:  Pathologe       Date:  2008-11       Impact factor: 1.011

Review 7.  Fragile histidine triad protein: structure, function, and its association with tumorogenesis.

Authors:  Md Imtaiyaz Hassan; Abdullah Naiyer; Faizan Ahmad
Journal:  J Cancer Res Clin Oncol       Date:  2009-12-24       Impact factor: 4.553

8.  Metastatic clear cell carcinoma of the kidney: therapeutic role of bevacizumab.

Authors:  Ronald M Bukowski
Journal:  Cancer Manag Res       Date:  2010-03-26       Impact factor: 3.989

Review 9.  Metastatic renal cell carcinoma.

Authors:  Robert C Flanigan; Steven C Campbell; Joseph I Clark; Maria M Picken
Journal:  Curr Treat Options Oncol       Date:  2003-10

Review 10.  Tyrosine kinase inhibitors and anti-angiogenic therapies in kidney cancer.

Authors:  Naomi B Haas; Robert G Uzzo
Journal:  Curr Treat Options Oncol       Date:  2007-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.